Published • loading... • Updated
Zenitar Announces the Commencement of an International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related Presentations at the 2026 ASH (American Society of Hematology) Meeting – Novumpr
Summary by Novumpr | En Nog Een WordPress Site
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CHENGDU, China–(BUSINESS WIRE)– Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing FM (flonoltinib maleate), an excellent oral JAK2/FLT3/CDK6 inhibitor for MPNs (myeloproliferative neoplasms), including MF (myelofibrosis) and PV (polycythemia vera). Zenitar launched a randomized Phase 2 FM-MF-02 (NCT07750574) in the United States, Canada, and Brazil to select Phase 3 dose for JAKi-naive and refractory MF. The […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
